Multiple HCPs have requested from Invivyd a monoclonal antibody (mAb) for treatment of active measles infection and post-exposure prophylaxis to reduce the consequence of outbreaks. Such a medicine ...

Invivyd, Inc. (NASDAQ:IVVD) shares gained in the premarket session on Monday after the company disclosed a $30 million term loan facility with Silicon Valley Bank (SVB), a division of First ...

WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that ...

WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist ...

expected growth in net product revenue, and ongoing reduction in manufacturing costs. Price Action: IVVD shares are down 0.78% at $0.50 at the last check on Monday.

Invivyd, Inc. (NASDAQ:IVVD) shares gained in the premarket session on Monday after the company disclosed a $30 million term loan facility with Silicon Valley Bank (SVB), a division of First Citizens ...

(RTTNews) - Invivyd (IVVD) has signed a $30 million term loan facility with Silicon Valley Bank, a division of First Citizens Bank. The deal allows for drawdown of capital in the future if certain ...

Invivyd, Inc. announced a $30 million term loan agreement with Silicon Valley Bank to support its biopharmaceutical initiatives, particularly in relation to its candidate monoclonal antibody ...

WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infe Invivyd Announces $30M Non ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...